Literature DB >> 28946014

Targeting BRAF in metastatic colorectal cancer: Maximizing molecular approaches.

John H Strickler1, Christina Wu2, Tanios Bekaii-Saab3.   

Abstract

Oncogenic mutations in B-type Raf kinase (BRAF) occur in 7-10% of metastatic colorectal cancers (mCRC). Despite recent improvements in survival in the general population of patients with mCRC, patients with BRAF-mutant mCRC continue to have poor response to most systemic therapies, and prognosis remains poor. There is a substantial unmet need for novel therapeutic strategies to treat patients with BRAF-mutant mCRC. This review outlines the epidemiology, molecular pathogenesis, prognosis, and mechanisms of treatment resistance of BRAF-mutated CRC. Additionally, this review highlights novel therapeutic strategies aimed at enhancing response and improving outcomes.
Copyright © 2017 The Author(s). Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  BRAF; Colorectal cancer; Targeted therapy

Mesh：

Substances：

Year:  2017        PMID： 28946014     DOI： 10.1016/j.ctrv.2017.08.006

Source DB:  PubMed          Journal:  Cancer Treat Rev        ISSN： 0305-7372            Impact factor:   12.111


  15 in total

Review 1.  Right Versus Left Colon Cancer: Resectable and Metastatic Disease.

Authors:  Michele Ghidini; Fausto Petrelli; Gianluca Tomasello
Journal:  Curr Treat Options Oncol       Date:  2018-05-23

2.  Can CT-based radiomics signature predict KRAS/NRAS/BRAF mutations in colorectal cancer?

Authors:  Lei Yang; Di Dong; Mengjie Fang; Yongbei Zhu; Yali Zang; Zhenyu Liu; Hongmei Zhang; Jianming Ying; Xinming Zhao; Jie Tian
Journal:  Eur Radiol       Date:  2018-01-15       Impact factor: 5.315

3.  The Molecular Basis of Metastatic Colorectal Cancer.

Authors:  Sarah F Andres; Kathy N Williams; Anil K Rustgi
Journal:  Curr Colorectal Cancer Rep       Date:  2018-03-01

Review 4.  The application of radiomics in predicting gene mutations in cancer.

Authors:  Yana Qi; Tingting Zhao; Mingyong Han
Journal:  Eur Radiol       Date:  2022-01-20       Impact factor: 5.315

5.  Genetic characterisation of molecular targets in carcinoma of unknown primary.

Authors:  B Clynick; B Dessauvagie; G Sterrett; N T Harvey; R J N Allcock; C Saunders; W Erber; K Meehan
Journal:  J Transl Med       Date:  2018-07-04       Impact factor: 5.531

6.  Synthesis and Biological Evaluation of New Madecassic Acid Derivatives Targeting ERK Cascade Signaling.

Authors:  Ana S C Valdeira; Daniel A Ritt; Deborah K Morrison; James B McMahon; Kirk R Gustafson; Jorge A R Salvador
Journal:  Front Chem       Date:  2018-09-28       Impact factor: 5.221

Review 7.  How to find the right drug for each patient? Advances and challenges in pharmacogenomics.

Authors:  Angeliki Kalamara; Luis Tobalina; Julio Saez-Rodriguez
Journal:  Curr Opin Syst Biol       Date:  2018-08

8.  Phase I, Open-Label, Dose-Escalation/Dose-Expansion Study of Lifirafenib (BGB-283), an RAF Family Kinase Inhibitor, in Patients With Solid Tumors.

Authors:  Jayesh Desai; Hui Gan; Catherine Barrow; Michael Jameson; Victoria Atkinson; Andrew Haydon; Michael Millward; Stephen Begbie; Michael Brown; Ben Markman; William Patterson; Andrew Hill; Lisa Horvath; Adnan Nagrial; Gary Richardson; Christopher Jackson; Michael Friedlander; Phillip Parente; Ben Tran; Lai Wang; Yunxin Chen; Zhiyu Tang; Wendy Huang; John Wu; Dewan Zeng; Lusong Luo; Benjamin Solomon
Journal:  J Clin Oncol       Date:  2020-03-17       Impact factor: 44.544

9.  LncRNA BANCR promotes tumorigenesis and enhances adriamycin resistance in colorectal cancer.

Authors:  Siping Ma; Dongxiang Yang; Yanlong Liu; Yongpeng Wang; Tao Lin; Yanxi Li; Shihua Yang; Wanchuan Zhang; Rui Zhang
Journal:  Aging (Albany NY)       Date:  2018-08-22       Impact factor: 5.682

10.  Complete response with fluorouracil and irinotecan with a BRAFV600E and EGFR inhibitor in BRAF-mutated metastatic colorectal cancer: a case report.

Authors:  Zhan Wang; Wei-Ping Dai; Yuan-Sheng Zang
Journal:  Onco Targets Ther       Date:  2019-01-08       Impact factor: 4.147
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.